Opinion|Videos|December 16, 2024

Spesolimab Efficacy Data

Key Takeaways

Panelists discuss how the efficacy data from the Effisayil 2 trial demonstrate that spesolimab significantly delayed the time to first GPP flare and reduced flare severity, highlighting its potential as an effective treatment for preventing life-threatening flares in GPP patients.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME